The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial

Mehri Jamilian1, Zohreh Tabassi2, Željko Reiner3, Ida Panahandeh2, Fatemeh Naderi2, Esma Aghadavod4, Elaheh Amirani3, Mohsen Taghizadeh3, Rana Shafabakhsh4, Mahbobeh Satari4, Mohammad Ali Mansournia5, Mohammad Reza Memarzadeh4 and Zatollah Asemi4*

1Traditional and Complementary Medicine Research Center, Arak University of Medical Sciences, PO Box 3848176941, Arak, Iran
2Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, PO Box 81151-87159, Kashan, Iran
3Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, 10-000 Zagreb, Croatia
4Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, PO Box 81151-87159, Kashan, Iran
5Department of Epidemiology and Biostatistics, School of Public Health, Tebran University of Medical Sciences, PO Box 1417613151, Tebran, Iran

(Submitted 21 May 2019 – Final revision received 23 November 2019 – Accepted 10 December 2019 – First published online 6 January 2020)

Abstract

The present study was performed to evaluate the effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus (GDM). This randomised, double-blind, placebo-controlled clinical trial was performed in sixty women with GDM. Participants were randomly divided into two groups to intake either 2 × 1000 mg/d n-3 fatty acids from flaxseed oil containing 400 mg α-linolenic acid in each capsule (n 30) or placebo (n 30) for 6 weeks. n-3 Fatty acid intake up-regulated PPAR-γ (P < 0.001) and LDL receptor (P = 0.004) and down-regulated gene expression of IL-1 (P = 0.002) and TNF-α (P = 0.001) in peripheral blood mononuclear cells of subjects with GDM. In addition, n-3 fatty acid supplementation reduced fasting plasma glucose (P = 0.001), insulin levels (P = 0.001) and insulin resistance (P < 0.001) and increased insulin sensitivity (P = 0.005) when compared with the placebo. Additionally, n-3 fatty acid supplementation was associated with a decrease in TAG (P < 0.001), VLDL-cholesterol (P < 0.001), total cholesterol (P = 0.01) and total cholesterol:HDL-cholesterol ratio (P = 0.01) when compared with placebo. n-3 Fatty acid administration was also associated with a significant reduction in high-sensitivity C-reactive protein (P = 0.006) and malondialdehyde (P < 0.001), and an increase in total nitrite (P < 0.001) and total glutathione levels (P = 0.006) when compared with the placebo. n-3 Fatty acid supplementation for 6 weeks to women with GDM had beneficial effects on gene expression related to insulin, lipid and inflammation, glycaemic control, lipids, inflammatory markers and oxidative stress.

Key words: Flaxseed oil: Gestational diabetes: Metabolic status: Insulin resistance: Inflammation

Gestational diabetes mellitus (GDM) is a condition in which glucose intolerance occurs in pregnant women without previously diagnosed diabetes mellitus. GDM is usually recognised in the second half of pregnancy(3). Based on the previous data, an increased risk of adverse perinatal consequences and a wide range of unfavourable long-term outcomes for mother and child are attributed to this condition(2). Strong evidence suggests a link between peripheral insulin resistance, changes of inflammatory cytokines and biomarkers of oxidative stress in the pathogenesis of GDM(3). Previous studies also suggested that both pre-existing maternal obesity and gestational diabetes are associated with decreased expression of transcription factors involved in carbohydrate and lipid metabolism such as PPAR, sterol regulatory element-binding protein 1c and increased gene expression levels of adipokines, TNF-α, IL-1β and leptin in adipose tissue(4). It has been shown that dietary interventions in GDM women

Abbreviations: ALA, α-linolenic acid; CRP, C-reactive protein; FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; LDLR, LDL receptor; MDA, malondialdehyde; VEGF, vascular endothelial growth factor.

* Corresponding author: Zatollah Asemi, fax +98 31 55465377, email asemi_r@yahoo.com
led to the reduced need for medication treatment, improved glycaemia and related parameters\(^5\).

Based on the available evidence, changes in long-chain PUFA, mainly n-6 and n-3 fatty acids, are associated with GDM and pregnancies complicated by pre-eclampsia and intra-uterine growth restriction\(^6\). A meta-analysis by Saccone \textit{et al.}\(^7\) indicated that n-3 fatty acid supplementation in pregnant women decreased C-reactive protein (CRP) levels and improved some pregnancy outcomes such as newborn's hyperbilirubinaemia and hospitalisation rate. Zhong \& Wang\(^8\) have recently demonstrated that in a meta-analysis, n-3 fatty acid supplementation in women with GDM significantly reduced fasting plasma glucose (FPG), homoeostasis model of assessment-insulin resistance and high-sensitive CRP (hs-CRP) levels but did not affect gestational age, the rate of preterm delivery and macrosomia, newborn's weight and 5-min Apgar score. The results of a meta-analysis suggested that n-3 fatty acid supplementation in patients with type 2 diabetes mellitus led to a significant improvement in HbA1c levels, serum lipids and inflammatory markers\(^9\). On the other hand, Jovanovski \textit{et al.}\(^10\) indicated that supplementation with α-linolenic acid (ALA) which is a precursor of PUFA present in plant oil had a neutral effect on parameters of glucose homeostasis. Our previous study indicated that a 6-week supplementation with 1000 mg fish oil enhanced gene expression of the PPAR-γ, LDL receptor (LDLR), TNF-α and IL-6\(^11\). Other studies investigated the effects of n-3 fatty acid supplementation on gene expression levels in different metabolic conditions. For example, ALA treatment of human renal cell carcinoma led to the up-regulation of PPAR-γ and reduced gene expression of cyclo-oxygenase-2\(^12\). Moreover, both flaxseed oil and fish oil have been reported to improve plasma TAG and PPAR-α gene expression and down-regulate the mRNA transcription of sterol regulatory element-binding protein-1 and inflammatory genes, including TNF-α and IL-6 in streptozotocin-induced diabetic rats\(^13\). However, flaxseed oil administration in sheep infected with \textit{Fasciola hepatica} did not influence neither production nor gene expression of inflammatory cytokines\(^14\).

Flaxseed oil is rich in ALA which is the precursor of long-chain n-3 fatty acids – PUFA: EPA and DHA\(^15\). Evidence suggests that the beneficial effects of flaxseed oil supplementation on metabolic profiles are achieved by the modulation of increased β-oxidation of fatty acids, reduced lipogenesis, enhanced immune function and antioxidant activity\(^16\). So far, the effect of flaxseed supplementation on metabolic and genetic profiles in GDM patients remains unknown. Therefore, the aim of the present study is to evaluate the effect of a 6-week supplementation with 2 g/d flaxseed oil on glycaemic control, lipid profile, parameters of inflammation and oxidative stress and gene expression related to metabolic profiles.

Methods

**Trial design and participants**

This research, registered in the Iranian website for clinical trials (http://www.irct.ir; IRCT201705130343941N42), was a randomised, double-blind, placebo-controlled clinical trial. Eligible subjects were aged 18–40 years (24–28 weeks of gestation) who were diagnosed with GDM through a ‘one-step’ diagnosis (FPG ≥ 5.1 mmol/l, 1-h oral glucose test tolerance ≥ 10 mmol/l and 2-h OGTT ≥ 8.5 mmol/l) based on the American Diabetes Association guidelines\(^17\). The exclusion criteria were women with eclampsia, pre-eclampsia, smokers, patients with thyroid disorders, kidney or liver diseases at enrolment and those starting with insulin therapy during intervention. The present study was performed in fifty-one women with GDM at 24–28 weeks’ gestation referred to the Kosar Clinic in Arak, Iran, between July 2018 and February 2019. The number of patients needed for the study was calculated based upon previously performed power analysis. The study was performed in accordance with the Declaration of Helsinki, and informed consent was obtained from all participants. The study got the approval of the ethics committee of Arak University of Medical Sciences.

**Study design**

Randomisation was performed to assign participants to two groups matched for BMI and age. Each woman was randomly assigned to one of the two groups to intake either 2 × 1000 mg/d n-3 fatty acids from flaxseed oil containing 400 mg ALA in each capsule (n 30) or placebo (n 30) for 6 weeks. We used the dose of 2000 mg n-3 fatty acids based on a previous study in women with polycystic ovary syndrome\(^18\). n-3 Fatty acid supplements and placebo (sunflower oil) were produced by Barij Essence Company. Patients were asked not to change their routine physical activity or usual dietary pattern throughout the study and not to take any anti-inflammatory and antioxidant medications or supplements that might affect their nutritional status during the 6-week intervention. Consumption of n-3 fatty acid supplements and placebo throughout the study was checked by asking subjects to return the medication containers. Furthermore, a short message was sent to the cell phones of all patients every day to remind participants to use the supplements. A 3-d food record and physical activity records were completed by all participants. The individual’s dietary intake was then calculated and calculated as average at weeks 0, 3 and 6 using Nutritionist IV software (First Databank) modified for Iranian foods. Physical activity was described as metabolic equivalents in h/d. To determine the metabolic equivalents for each participant, we multiplied the times (in h/d) reported for each physical activity by its related metabolic equivalents coefficient using standard tables\(^19\).

**Assessment of anthropometric measures**

A trained staff at the clinic took anthropometric parameters at the beginning of the study and 6 weeks after the intervention. Body weight was measured after an overnight fast using the same digital scale (Seca).

**Assessment of outcomes**

We considered gene expression of PPAR-γ as the primary outcome and other metabolic and genetic profiles as secondary outcomes. Fasting blood samples (20 ml) were collected at baseline and 6 weeks after the intervention at Arak reference
laboratory. Then, the samples were stored at −80°C before analysis. Serum insulin levels were assessed by the use of a chimerical ELISA kit (DiaMetra) with inter- and intra-assay CV below 5%. Homoeostasis model of assessment-insulin resistance and the quantitative insulin sensitivity check index were determined using the standard formula. Enzymatic kits of Pars Azmun were used to evaluate FPG and serum lipids with inter- and intra-assay CV below 5%. Serum levels of hs-CRP were determined by a commercial ELISA kit (LDN) with inter- and intra-assay CV below 7%. Plasma total nitrite was determined using the Griess method, total antioxidant capacity using the method of ferric-reducing antioxidant power developed by Benzie & Strain, and malondialdehyde (MDA) concentrations were determined by the thiobarbituric acid reactive substances spectrophotometric test with inter- and intra-assay CV below 5%.

### Isolation of lymphocyte, RNA extraction and complementary DNA synthesis

Lymphocytes were isolated using 50% Percoll solution (Sigma-Aldrich) gradient by centrifugation for 20 min and 3000 rpm at 4°C. Total RNA was extracted based on acid guanidinium–phenol–chloroform procedure using an RNX™ plus reagent (Cinnacolon) according to the manufacturer’s instructions. RNA was treated with DNase I (Fermentas) for elimination of any genomic DNA contamination. A total of 3 mg of RNA was used for complementary DNA synthesis with random hexamer and oligo (dT) 18 primers through RevertAid™ Reverse Transcriptase (Fermentase) in 20 μl reaction mixture.

### Real-time PCR analysis

Appropriate primers for PPAR-γ, LDLR, IL-1, IL-8, TNF-α, transforming growth factor β, vascular endothelial growth factor (VEGF) and glyceraldehyde 3-phosphate dehydrogenase were designed (Table 1). Quantitative real-time PCR was performed by the LightCycler® 96 sequence detection systems (Roche Diagnostics) using 4 μl of 5 x EVA GREEN I master mix (Salise Biodyne), 10 ng complementary DNA, 200 nM of each forward and reverse primers in a volume of 20 μl.

### Sample size

In the present study, we used a randomised clinical trial sample size calculation formula where type one (α) and type two errors (β) were 0.05 and 0.20 (power = 80%), respectively. Based upon our previous trial, we used 0.25 as the sd and 0.20 as the change in mean (d) of PPAR-γ as a primary outcome. Based on the power analysis, we needed twenty-five subjects in each group. After allowing for five dropouts in each group, the final sample size was thirty subjects in each group.

### Randomisation

Randomisation was performed using computer-generated random numbers. Randomisation and allocation were hidden from the researchers and pregnant women until the final analyses were completed. The randomised allocation sequence, enrolling participants and allocating them to intervention were carried out by a trained midwife at the clinic.

### Statistical methods

The Kolmogorov–Smirnov test was done to determine the normality of data. To detect the differences in anthropometric parameters, dietary intakes and gene expression related to insulin, lipids and inflammation markers between groups, we used the independent-samples t test. Multiple linear regression models were used to evaluate treatment effects on variables after adjusting for confounding variables, including baseline values of biochemical variables. We have used linear regression models with follow-up values of outcomes as the response (dependent) variable and treatment group, baseline values of the outcomes, and other potential confounders including age and BMI at baseline as explanatory (independent) variables. The effect sizes were presented as the mean differences with 95% CI. P-values <0.05 were considered statistically significant. All statistical

### Table 1. Specific primers used for real-time quantitative PCR

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer</th>
<th>Product size (bp)</th>
<th>Annealing temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>F: AAGCTCATTTTCTGATGAGGAACG 126</td>
<td>R: TCTCTCTTTCTGCTTCTGAGG</td>
<td>61.3</td>
</tr>
<tr>
<td>PPAR-γ</td>
<td>F: ATGACGACCTCTCAAGACTTG 210</td>
<td>R: ATGTTGGCAAGTGCCCTCAG</td>
<td>54</td>
</tr>
<tr>
<td>LDLR</td>
<td>F: ACCACGGAAGACAGACAGACAG 223</td>
<td>R: GGCACACACTCCGTGAGAG</td>
<td>57</td>
</tr>
<tr>
<td>IL-1</td>
<td>F: GCTTCTCTCGTCCTGGTG 174</td>
<td>R: AGGCGCAGTGAGAG</td>
<td>56</td>
</tr>
<tr>
<td>TNF-α</td>
<td>F: GTCAACCTCTCTCCTGCATC 188</td>
<td>R: CCAAAGTGACACTTGCCAGA</td>
<td>52</td>
</tr>
<tr>
<td>TGF-β</td>
<td>F: TTGAGACCTTTTTCTGAGGCGG 227</td>
<td>R: CGAGGCTGCGGGAAAAAGTCT</td>
<td>56</td>
</tr>
<tr>
<td>VEGF</td>
<td>F: CTCTCCAGTGGCCCGAGAGA 216</td>
<td>R: CTCCAACACACACACACAG</td>
<td>54</td>
</tr>
</tbody>
</table>

GAPDH, glyceraldehyde-3-phosphate dehydrogenase; F, forward; R, reverse; LDLR, LDL receptor; TGF-β, transforming growth factor β; VEGF, vascular endothelial growth factor.
analyses were done using the Statistical Package for Social Science version 18 (SPSS Inc.).

Results

Among individuals in the $n$-3 fatty acids group, four persons due to personal reasons were excluded (Fig. 1). In the placebo group, five participants were also excluded due to personal reasons. Fifty-one participants completed the trial. The compliance rate in our study was high; participants reported that more than 90% of both $n$-3 fatty acids and placebo capsules were taken during the trial. No side effects were reported following the intake of $n$-3 fatty acids in patients with GDM throughout the study.

Mean age, height, weight and BMI at the beginning of the study and mean weight and BMI after intervention were not statistically different between the two groups (Table 2).

Based on the 3-d dietary records obtained during the trial, there were no significant changes in dietary macro- and micronutrient intakes (data not shown). Moreover, there was no significant change in the mean $n$-3 dietary intake at baseline (1·11 (sd 0·20) for the $n$-3 group v. 1·04 (sd 0·17) g/d for the placebo group, $P=0·18$).

$n$-3 Fatty acid intake up-regulated PPAR-γ ($P<0·001$) and LDLR ($P=0·004$) and down-regulated gene expression of IL-1 ($P=0·002$) and TNF-α ($P=0·001$) in peripheral blood mononuclear cells of subjects with GDM (Figs. 2 and 3). $n$-3 Fatty acid supplementation did not affect transforming growth factor β and VEGF expression.

After the 6-week intervention, $n$-3 fatty acid supplementation reduced FPG ($β=0·26$ mmol/l; 95% CI $−0·42$; $0·11$; $P=0·001$), insulin levels ($β=15·56$ pmol/l; 95% CI $−24·4$; $6·75$; $P=0·001$) and homoeostasis model of assessment-insulin resistance ($β=−0·63$; 95% CI $−0·92$; $0·33$; $P<0·001$) and increased quantitative insulin sensitivity check index ($β=0·01$; 95% CI $0·003$; 0·01; $P=0·005$) when compared with placebo (Table 3). $n$-3 Fatty acid supplementation was associated with a decrease in TAG ($β=−0·46$ mmol/l; 95% CI $−0·69$; $−0·22$; $P<0·001$), VLDL-cholesterol ($β=−0·21$ mmol/l; 95% CI $−0·32$; $−0·10$; $P<0·001$), total cholesterol ($β=−0·58$ mmol/l; 95% CI $−1·04$; $0·12$; $P=0·01$) and total cholesterol: HDL-cholesterol ratio ($β=−0·58$; 95% CI $−1·06$; $0·11$; $P=0·01$) when compared with placebo. Finally, $n$-3 fatty acid administration caused a significant reduction in hs-CRP ($β=−1·27$ mg/l; 95% CI $−2·17$; $−0·38$; $P=0·006$) and MDA ($β=−0·47$ μmol/l; 95% CI $−0·69$; $−0·25$; $P<0·001$) and a significant elevation in total nitrite ($β=5·42$ μmol/l; 95% CI 3·84; 7·00;
Fig. 2. Fold change in gene expression levels of PPAR-γ and LDL receptor (LDLR) in women with gestational diabetes mellitus who received probiotic supplements and placebo. Values are means, with standard deviations represented by vertical bars. *P* values were obtained from independent *t* tests. □ Placebo; ■ n-3.

Fig. 3. Change in gene expression levels of IL-1, TNF-α, transforming growth factor β (TGF-β) and vascular endothelial growth factor (VEGF) in women with gestational diabetes mellitus who received probiotic supplements and placebo. Values are means, with standard deviations represented by vertical bars. *P* values were obtained from independent *t* tests. □ Placebo; ■ n-3.

Table 3. Metabolic profiles, biomarkers of inflammation and oxidative stress at baseline and after the 6-week intervention in patients with gestational diabetes mellitus who received either flaxseed oil supplements or placebo (Mean values and standard deviations; *β*-coefficients and 95% confidence intervals)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Placebo group (n=25)</th>
<th>Probiotic group (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Week 6</td>
</tr>
<tr>
<td>FPG (mmol/l)</td>
<td>Mean</td>
<td>sd</td>
</tr>
<tr>
<td>Insulin (pmol/l)</td>
<td>5.07</td>
<td>0.29</td>
</tr>
<tr>
<td>(mg/l)</td>
<td>93.8</td>
<td>29.9</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.1</td>
<td>1.1</td>
</tr>
<tr>
<td>QUICKI</td>
<td>0.32</td>
<td>0.02</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>0.23</td>
<td>0.07</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>1.02</td>
<td>0.32</td>
</tr>
<tr>
<td>Total nitrite (μmol/l)</td>
<td>5.40</td>
<td>1.35</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>3.06</td>
<td>1.25</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.12</td>
<td>0.18</td>
</tr>
<tr>
<td>Total cholesterol:LDL-cholesterol ratio</td>
<td>3.28</td>
<td>1.10</td>
</tr>
<tr>
<td>hs-CRP (mg/l)</td>
<td>5.4</td>
<td>2.1</td>
</tr>
<tr>
<td>Total nitrite (μmol/l)</td>
<td>31.4</td>
<td>4.2</td>
</tr>
<tr>
<td>TAC (mmol/l)</td>
<td>679.6</td>
<td>71.4</td>
</tr>
<tr>
<td>GSH (μmol/l)</td>
<td>457.4</td>
<td>84.2</td>
</tr>
<tr>
<td>MDA (μmol/l)</td>
<td>2.8</td>
<td>0.5</td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; QUICKI, quantitative insulin sensitivity check index; hs-CRP, high-sensitivity C-reactive protein; TAC, total antioxidant capacity; MDA, malondialdehyde.

* Outcome measures refer to the change in values of measures of interest between baseline and week 6. *β* (difference in the mean outcome’s measures between treatment groups (flaxseed oil group = 1 and placebo group = 0)).

† Obtained from the multiple regression model (adjusted for baseline values of each biochemical variables).
**Effects on biomarkers of inflammation and oxidative stress**

The present study showed that the ingestion of flaxseed oil by women with GDM caused a significant decrease in TNF-α and IL-1 expression. It was also effective in improving hs-CRP, NO, GSH and MDA but did not affect total antioxidant capacity values and gene expression of transforming growth factor β and VEGF.

Previously, we have observed that 1000 mg/d fish oil supplementation for 6 weeks decreased gene expression of TNF-α and IL-6 in patients with GDM(41). It has been reported that both flaxseed oil and fish oil supplementation in streptozotocin-induced diabetic rats improved down-regulated mRNA expression of genes for TNF-α and IL-6(42). A 12-week flaxseed oil supplementation at a dosage of 2 g/d in type 2 diabetes mellitus patients with CHD decreased TNF-α and IL-1 expression but did not change transforming growth factor β and VEGF expression(43). However, flaxseed oil administration in sheep infected with *F. hepatica* did not affect production or gene expression of IL-4 and interferon-γ(44). Similar to our findings, Zhao & Wang(45) found that n-3 fatty acids applied as a part of parenteral nutrition in postoperative patients with gastrointestinal malignancy decreased CRP and other inflammatory markers. An *in vitro* study demonstrated that peripheral blood lymphocytes of women with GDM when exposed to n-3 fatty acids caused elevated GSH and decreased MDA cell levels(46). A 12-week n-3 fatty acid supplementation with 2 g/d flaxseed oil improved hs-CRP and GSH levels in patients with grade 3 diabetic foot ulcer(47). Our previous study indicated that 1000 mg n-3 fatty acids from flaxseed oil plus 360 mg vitamin E supplementation to women with GDM increased NO levels and decreased MDA concentrations but did not affect hs-CRP and GSH levels(48). Our findings differ from the results of previous meta-analyses which suggested that supplementation with flaxseed and its derivatives(49) and ALA(50) did not reduce CRP circulating levels. In addition, in contrast to our findings, a 6-week flaxseed oil supplementation at a dosage of 6 g/d did not improve oxidative stress markers in haemodialysis patients(51). The evidence proposed that flaxseed oil supplementation may improve inflammation and oxidative stress via reduction of NF-κB-induced gene expression(52), modification of mitogen-activated protein kinase and protein kinase B signalling pathways(53) and enhancement of NADPH oxidase activity(54). In our study, beneficial effects on cardio-metabolic markers may be due to the type of n-3 fatty acids used and baseline levels of biochemical variables. However, data on the effects of n-3 fatty acids from flaxseed oil are limited. As there are multiple metabolic disorders such as insulin resistance, dyslipidaemia, increased inflammatory markers and oxidative stress which occur during pregnancy, especially in women with GDM, n-3 fatty acids may have better effects than in other metabolic diseases. Also, several studies used higher doses than 2 g/d – up to 4 g/d of n-3 fatty acids from fish oil in patients with metabolic disorders(46). Studies with longer duration of the intervention are needed to confirm our findings.

The present study has some limitations. We could not measure fatty acid profiles at baseline and at the end of the trial. However, the total amount of dietary n-3 fatty acid intake was not different between the placebo group and the group taking

$P < 0.001$ and GSH levels (β 116-55 μmol/l; 95% CI 34-36, 198-74; $P = 0.006$) when compared with placebo. In addition, when we adjusted the analysis for baseline variables, age, baseline BMI and mean n-3 intake at baseline study and findings did not alter (data not shown).

**Discussion**

In the present study, we investigated the effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in subjects with GDM. We found that n-3 fatty acid supplementation during 6 weeks to women with GDM had beneficial effects on gene expression related to insulin, lipids, glycaemic control, inflammatory markers and oxidative stress.

**Effects on glycaemic control and lipids**

GDM is associated with changes, including increased insulin resistance, dyslipidaemia, oxidative stress and inflammatory state(55). We observed a significant improvement in PPAR-γ and LDLR mRNA expression as well as parameters of glycaemic control, TAG, VLDL-cholesterol, total cholesterol and total cholesterol:HDL-cholesterol ratio. However, we were unable to find any significant effects on other serum lipids following flaxseed supplementation in women with GDM. There are several studies investigating the effects of n-3 fatty acids on gene expression of proteins involved in carbohydrates and lipid metabolism. Our previous study indicated that 6-week supplementation with 1000 mg/d fish oil enhanced gene expression of the PPAR-γ and LDLR in GDM women(11). The treatment of human renal cell carcinoma with ALA up-regulated the PPAR-γ gene expression(12). Ebrahimi *et al.*(27) reported that linseed oil increased gene expression of the PPAR-γ in goats. A meta-analysis by Zhong & Wang(46) showed that n-3 fatty acid supplementation in GDM patients significantly reduced FPG score which is in accordance with our results. n-3 Fatty acid supplementation in type 2 diabetes mellitus patients caused a significant improvement in TAG, VLDL-cholesterol and HDL-cholesterol levels(9). In some studies, n-3 fatty acid supplementation in patients with non-alcoholic fatty liver disease(20) and polycystic ovary syndrome(29) decreased plasma TAG levels. However, in contrast to our findings, Jovanovski *et al.*(10) indicated that ALA did not affect glycaemic control. In pregnant women, hyperglycaemia and dyslipidaemia are associated with adverse clinical consequences for mother and neonates(29). Correction of glycaemic control and serum lipids in women with GDM is associated with reduced risk for many important adverse pregnancy outcomes such as gestational hypertension, macrosomia, large for gestational age births and shoulder dystocia and may provide long-lasting health benefits(31). In this context, the activity of PPAR-γ is important because of its regulatory effects on the gene expression of carboxykinase, glucose-6-phosphatase and fatty acid transporter-1, which cause decreased production of NEFA and improved insulin sensitivity(32). n-3 Fatty acid supplementation increases β-oxidation of fatty acids, reduces lipogenesis, improves antioxidant functions and facilitates insulin action(33).
supplements so that the observed effect was clearly due to the supplement intake and not due to the changes in the diet. Because of funding limitations, we could not assess gene expression related to oxidative stress.

Conclusions

n-3 Fatty acid supplementation during 6 weeks to women with GDM had beneficial effects on gene expression related to insulin, lipids, glycaemic control, inflammatory markers and oxidative stress.

Acknowledgements

The authors would like to thank the staff of Kosar Clinic (Arak, Iran) for their assistance in this project.

The research grant was provided by Research Deputy of Arak University of Medical Sciences.


The authors declare no conflicts of interest.

References